← Back to Search

Checkpoint Inhibitor

Pre-Surgery Immunotherapy for Mesothelioma

Phase 2
Recruiting
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >= 18 years
STEP 2 ELIGIBILITY CRITERIA: Completion of at least 1 cycle of treatment and not have an unresolved adverse event that would preclude surgery
Must not have
No patients with chest wall invasion, peritoneal spread, contralateral pleural involvement, mediastinal organ involvement, vertebral involvement, or metastases to contralateral intrathoracic lymph nodes, or any supraclavicular nodes
No patients deemed to be unresectable or poor surgical candidates
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if giving immunotherapy drugs can better control disease in patients with a specific type of mesothelioma. The drugs help the immune system attack cancer cells, which may stop the cancer from growing and spreading.

Who is the study for?
This trial is for adults with stage I-IIIa sarcomatoid mesothelioma who haven't had prior treatments affecting the primary tumor. Candidates must have a stable HIV, no active infections or autoimmune diseases (with some exceptions), and an ECOG performance status of <=2 or Karnofsky >=60%. Pregnant or nursing women are excluded, as well as those with certain heart conditions or other health issues that could interfere with surgery.
What is being tested?
The trial tests if giving immunotherapy drugs nivolumab and ipilimumab before surgery can better control sarcomatoid mesothelioma compared to immunotherapy alone. These drugs may boost the immune system's ability to fight cancer by targeting specific proteins on tumor cells.
What are the potential side effects?
Potential side effects from nivolumab and ipilimumab include fatigue, diarrhea, skin rash, itching, hormone gland problems (like thyroid dysfunction), liver inflammation, lung issues like pneumonitis, colitis in the digestive tract, and possible infusion-related reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I've completed at least 1 treatment cycle and am fit for surgery.
Select...
I do not have any active infections needing treatment and I tested negative for hepatitis B and C.
Select...
I don't have conditions that need TNFalpha or immunosuppressant treatments.
Select...
My cancer is mostly sarcomatoid mesothelioma.
Select...
I am mostly self-sufficient and can carry out daily activities.
Select...
I am not pregnant or breastfeeding.
Select...
My cancer is at an early to mid-stage according to UICC standards.
Select...
I can take care of myself but might not be able to do active work.
Select...
My cancer has not progressed to a stage that makes surgery impossible.
Select...
My kidney function, measured by creatinine levels or clearance, is within the normal range.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has not spread to my chest wall, abdomen, opposite lung side, mid-chest organs, spine, or above my collarbone.
Select...
I am considered a good candidate for surgery.
Select...
I have never had symptomatic interstitial lung disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression free survival (PFS)
Surgery Rate
Secondary study objectives
Incidence of adverse events
Major pathologic response
Objective response rate
+1 more
Other study objectives
Biomarkers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (nivolumab, ipilimumab, surgery)Experimental Treatment6 Interventions
Patients receive nivolumab IV, ipilimumab IV, and may undergo surgery on study. Patients also undergo CT or MRI and PET throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ipilimumab
2014
Completed Phase 3
~3140
Surgical Procedure
2020
Completed Phase 2
~160
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Positron Emission Tomography
2011
Completed Phase 2
~2200
Computed Tomography
2017
Completed Phase 2
~2740
Nivolumab
2014
Completed Phase 3
~5220

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Mesothelioma include chemotherapy, radiation therapy, and immune checkpoint inhibitors. Immune checkpoint inhibitors, such as Nivolumab and Ipilimumab, work by blocking proteins that prevent the immune system from attacking cancer cells. Nivolumab targets the PD-1 protein, while Ipilimumab targets the CTLA-4 protein. By inhibiting these checkpoints, these drugs enhance the body's immune response against cancer cells. This is particularly important for Mesothelioma patients as it offers a novel approach to control the disease, especially in cases where traditional treatments are ineffective. These therapies can potentially improve survival rates and quality of life for patients with this aggressive cancer.
Novel and Future Treatment Options in Mesothelioma: A Systematic Review.

Find a Location

Who is running the clinical trial?

Alliance for Clinical Trials in OncologyLead Sponsor
515 Previous Clinical Trials
219,850 Total Patients Enrolled
7 Trials studying Mesothelioma
713 Patients Enrolled for Mesothelioma
National Cancer Institute (NCI)NIH
13,879 Previous Clinical Trials
41,013,220 Total Patients Enrolled
93 Trials studying Mesothelioma
8,587 Patients Enrolled for Mesothelioma

Media Library

Ipilimumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05647265 — Phase 2
Mesothelioma Research Study Groups: Treatment (nivolumab, ipilimumab, surgery)
Mesothelioma Clinical Trial 2023: Ipilimumab Highlights & Side Effects. Trial Name: NCT05647265 — Phase 2
Ipilimumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05647265 — Phase 2
~2 spots leftby Dec 2024